PT2465950T - Mutações de k-ras e terapia de anticorpo anti-egfr - Google Patents

Mutações de k-ras e terapia de anticorpo anti-egfr

Info

Publication number: PT2465950T
Authority: PT; Portugal
Prior art keywords: egfr antibody; antibody therapy; ras mutations; ras; mutations
Prior art date: 2007-03-13

Application number

PT121541098T

Other languages

English (en)

Inventor

Freeman Daniel

Juan Todd

Radinsky Robert

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-13

Filing date

2008-03-11

Publication date

2017-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39689242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2465950(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-03-11 Application filed by Amgen Inc filed Critical Amgen Inc

2017-10-17 Publication of PT2465950T publication Critical patent/PT2465950T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

PT121541098T 2007-03-13 2008-03-11 Mutações de k-ras e terapia de anticorpo anti-egfr PT2465950T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US90694307P	2007-03-13	2007-03-13

Publications (1)

Publication Number	Publication Date
PT2465950T true PT2465950T (pt)	2017-10-17

Family

ID=39689242

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT87420618T PT2121989E (pt)	2007-03-13	2008-03-11	Novo derivado de triazina e composição farmacéutica que contém o mesmo
PT121541098T PT2465950T (pt)	2007-03-13	2008-03-11	Mutações de k-ras e terapia de anticorpo anti-egfr

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT87420618T PT2121989E (pt)	2007-03-13	2008-03-11	Novo derivado de triazina e composição farmacéutica que contém o mesmo

Country Status (21)

Country	Link
US (3)	US20080293055A1 (pt)
EP (2)	EP2465950B1 (pt)
JP (1)	JP2010521153A (pt)
AR (1)	AR065687A1 (pt)
AU (1)	AU2008226803A1 (pt)
CA (1)	CA2680326A1 (pt)
CL (1)	CL2008000717A1 (pt)
CY (2)	CY1115333T1 (pt)
DK (2)	DK2465950T3 (pt)
ES (2)	ES2635051T3 (pt)
HR (2)	HRP20140360T4 (pt)
HU (1)	HUE033695T2 (pt)
LT (1)	LT2465950T (pt)
MX (1)	MX2009009787A (pt)
PE (1)	PE20081880A1 (pt)
PL (2)	PL2121989T5 (pt)
PT (2)	PT2121989E (pt)
RS (2)	RS53265B2 (pt)
SI (2)	SI2121989T2 (pt)
TW (1)	TW200902553A (pt)
WO (1)	WO2008112269A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1917528B1 (en) *	2005-08-24	2011-08-17	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8768629B2 (en)	2009-02-11	2014-07-01	Caris Mpi, Inc.	Molecular profiling of tumors
CN103424541B (zh)	2006-05-18	2018-01-30	分子压型学会股份有限公司	确定针对病状的个性化医疗介入的系统和方法
SI2412828T1 (sl) *	2007-03-13	2013-10-30	Amgen Inc.	Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
EP3216874A1 (en)	2008-09-05	2017-09-13	TOMA Biosciences, Inc.	Methods for stratifying and annotating cancer drug treatment options
WO2010056337A2 (en)	2008-11-12	2010-05-20	Caris Mpi, Inc.	Methods and systems of using exosomes for determining phenotypes
US8502015B1 (en)	2009-07-06	2013-08-06	Transgenex Nanobiotech, Inc.	Method of inducing cancer
CN102115782B (zh) *	2009-12-30	2014-06-18	北京雅康博生物科技有限公司	用于定量检测K-ras突变的试剂盒
CN103237901B (zh)	2010-03-01	2016-08-03	卡里斯生命科学瑞士控股有限责任公司	用于治疗诊断的生物标志物
WO2011127219A1 (en)	2010-04-06	2011-10-13	Caris Life Sciences Luxembourg Holdings	Circulating biomarkers for disease
KR20120140252A (ko) *	2010-04-12	2012-12-28	리스판스 지네틱스, 인크.	Ｋｒａｓ 프라이머 및 프로브
IN2013MN00522A (pt)	2010-09-24	2015-05-29	Univ Leland Stanford Junior
SG194111A1 (en)	2011-04-07	2013-11-29	Amgen Inc	Novel egfr binding proteins
EP2776043B1 (en) *	2011-11-11	2018-02-21	Millennium Pharmaceuticals, Inc.	Biomarkers of response to proteasome inhibitors
US20160040229A1 (en)	2013-08-16	2016-02-11	Guardant Health, Inc.	Systems and methods to detect rare mutations and copy number variation
US10876152B2 (en)	2012-09-04	2020-12-29	Guardant Health, Inc.	Systems and methods to detect rare mutations and copy number variation
US11913065B2 (en)	2012-09-04	2024-02-27	Guardent Health, Inc.	Systems and methods to detect rare mutations and copy number variation
ES2769241T5 (es)	2012-09-04	2023-05-30	Guardant Health Inc	Sistemas y métodos para detectar variación en el número de copias
US20140199405A1 (en) *	2013-01-11	2014-07-17	Abraxis Bioscience, Llc	Method for treating cancer based on mutation status of k-ras
WO2014148557A1 (ja) *	2013-03-19	2014-09-25	凸版印刷株式会社	Ｅｇｆｒ阻害剤感受性予測方法
CN111534580B (zh)	2013-12-28	2024-06-04	夸登特健康公司	用于检测遗传变异的方法和系统
EP3143163B1 (en)	2014-05-13	2020-11-25	Board of Regents, The University of Texas System	Gene mutations and copy number alterations of egfr, kras and met
CA3008651A1 (en)	2015-12-17	2017-06-22	Guardant Health, Inc.	Methods to determine tumor gene copy number by analysis of cell-free dna
US12246067B2 (en)	2018-06-19	2025-03-11	Biontech Us Inc.	Neoantigens and uses thereof
CN110357965A (zh) *	2019-06-24	2019-10-22	浙江大学	一种突变型kras特异性抗体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
EP0636186B1 (en)	1992-04-03	1998-11-25	The Perkin-Elmer Corporation	Probe composition and method
US5470705A (en)	1992-04-03	1995-11-28	Applied Biosystems, Inc.	Probe composition containing a binding domain and polymer chain and methods of use
EP2314625B1 (en)	1996-12-03	2014-05-07	Amgen Fremont Inc.	Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO2000055368A2 (en)	1999-03-15	2000-09-21	Pe Corporation (Ny)	Probe/mobility modifier complexes for multiplex nucleic acid detection
AU2001265121A1 (en)	2000-05-30	2001-12-11	Applera Corporation	Methods for detecting target nucleic acids using coupled ligation and amplification
US6503914B1 (en) *	2000-10-23	2003-01-07	Board Of Regents, The University Of Texas System	Thienopyrimidine-based inhibitors of the Src family
WO2003099205A2 (en)	2002-05-20	2003-12-04	Abgenix, Inc.	Treatment of renal carcinoma using antibodies against the egfr
AU2004248140A1 (en)	2003-05-30	2004-12-23	Cedars-Sinai Medical Center	Gene expression markers for response to EGFR inhibitor drugs
DK2439285T3 (da)	2004-03-31	2019-07-29	Massachusetts Gen Hospital	Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor
WO2005118876A2 (en) *	2004-06-04	2005-12-15	Genentech, Inc.	Egfr mutations
US20060088871A1 (en) *	2004-10-22	2006-04-27	Finkelstein Sydney D	Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
JP2008536493A (ja)	2005-04-01	2008-09-11	アムジエン・インコーポレーテツド	上皮増殖因子受容体遺伝子のコピー数
RU2007141067A (ru) *	2005-04-14	2009-05-20	Мерк Патент ГмбХ (DE)	Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
US20090202989A1 (en) *	2005-06-28	2009-08-13	Hillan Kenneth J	Egfr and kras mutations
WO2007011702A2 (en) *	2005-07-15	2007-01-25	The University Of North Carolina At Chapel Hill	Use of egfr inhibitors to prevent or treat obesity
EP1917528B1 (en) *	2005-08-24	2011-08-17	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US7908091B2 (en) *	2006-03-17	2011-03-15	Prometheus Laboratories Inc.	Methods of predicting and monitoring tyrosine kinase inhibitor therapy
WO2008033442A2 (en) *	2006-09-12	2008-03-20	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for performing low background multiplex nucleic acid amplification reactions
SI2412828T1 (sl) *	2007-03-13	2013-10-30	Amgen Inc.	Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr

2008
- 2008-03-11 LT LTEP12154109.8T patent/LT2465950T/lt unknown
- 2008-03-11 CL CL200800717A patent/CL2008000717A1/es unknown
- 2008-03-11 PL PL08742061.8T patent/PL2121989T5/pl unknown
- 2008-03-11 CA CA002680326A patent/CA2680326A1/en not_active Abandoned
- 2008-03-11 AR ARP080100995A patent/AR065687A1/es unknown
- 2008-03-11 US US12/046,319 patent/US20080293055A1/en not_active Abandoned
- 2008-03-11 PE PE2008000451A patent/PE20081880A1/es not_active Application Discontinuation
- 2008-03-11 PL PL12154109T patent/PL2465950T3/pl unknown
- 2008-03-11 RS RS20140187A patent/RS53265B2/sr unknown
- 2008-03-11 PT PT87420618T patent/PT2121989E/pt unknown
- 2008-03-11 EP EP12154109.8A patent/EP2465950B1/en active Active
- 2008-03-11 RS RS20170996A patent/RS56422B1/sr unknown
- 2008-03-11 HU HUE12154109A patent/HUE033695T2/en unknown
- 2008-03-11 ES ES12154109.8T patent/ES2635051T3/es active Active
- 2008-03-11 JP JP2009553623A patent/JP2010521153A/ja active Pending
- 2008-03-11 EP EP08742061.8A patent/EP2121989B2/en active Active
- 2008-03-11 MX MX2009009787A patent/MX2009009787A/es active IP Right Grant
- 2008-03-11 SI SI200831191T patent/SI2121989T2/sl unknown
- 2008-03-11 AU AU2008226803A patent/AU2008226803A1/en not_active Abandoned
- 2008-03-11 WO PCT/US2008/003312 patent/WO2008112269A2/en not_active Ceased
- 2008-03-11 DK DK12154109.8T patent/DK2465950T3/en active
- 2008-03-11 PT PT121541098T patent/PT2465950T/pt unknown
- 2008-03-11 SI SI200831873T patent/SI2465950T1/sl unknown
- 2008-03-11 ES ES08742061T patent/ES2458626T5/es active Active
- 2008-03-11 TW TW097108519A patent/TW200902553A/zh unknown
- 2008-03-11 DK DK08742061.8T patent/DK2121989T4/da active
- 2008-03-11 HR HRP20140360TT patent/HRP20140360T4/hr unknown
2012
- 2012-06-14 US US13/523,174 patent/US10030270B2/en active Active
2014
- 2014-04-16 CY CY20141100291T patent/CY1115333T1/el unknown
2017
- 2017-07-25 CY CY20171100792T patent/CY1119112T1/el unknown
- 2017-10-09 HR HRP20171509TT patent/HRP20171509T1/hr unknown
2018
- 2018-06-21 US US16/014,056 patent/US11155876B2/en active Active

Also Published As

Publication number	Publication date
US11155876B2 (en)	2021-10-26
PT2121989E (pt)	2014-04-30
PE20081880A1 (es)	2008-12-31
HRP20140360T4 (hr)	2022-06-10
RS53265B (sr)	2014-08-29
DK2121989T3 (da)	2014-04-28
LT2465950T (lt)	2017-10-10
EP2121989B1 (en)	2014-01-22
US20190048423A1 (en)	2019-02-14
ES2635051T3 (es)	2017-10-02
CY1115333T1 (el)	2017-01-04
US10030270B2 (en)	2018-07-24
AU2008226803A1 (en)	2008-09-18
ES2458626T5 (es)	2022-04-29
CY1119112T1 (el)	2018-02-14
MX2009009787A (es)	2009-09-22
JP2010521153A (ja)	2010-06-24
PL2121989T5 (pl)	2023-03-06
EP2121989A2 (en)	2009-11-25
SI2121989T2 (sl)	2022-05-31
AR065687A1 (es)	2009-06-24
ES2458626T3 (es)	2014-05-06
SI2465950T1 (sl)	2017-11-30
TW200902553A (en)	2009-01-16
WO2008112269A2 (en)	2008-09-18
RS53265B2 (sr)	2022-06-30
SI2121989T1 (sl)	2014-06-30
HRP20171509T1 (hr)	2017-11-17
EP2465950A3 (en)	2013-03-13
HUE033695T2 (en)	2017-12-28
HRP20140360T1 (hr)	2014-05-23
CL2008000717A1 (es)	2008-09-22
EP2465950B1 (en)	2017-07-12
EP2465950A2 (en)	2012-06-20
DK2121989T4 (da)	2022-06-20
WO2008112269A3 (en)	2008-11-20
US20080293055A1 (en)	2008-11-27
PL2121989T3 (pl)	2014-07-31
RS56422B1 (sr)	2018-01-31
US20120264129A1 (en)	2012-10-18
CA2680326A1 (en)	2008-09-18
EP2121989B2 (en)	2022-03-09
PL2465950T3 (pl)	2017-12-29
DK2465950T3 (en)	2017-10-09

Publication	Publication Date	Title
SI2465950T1 (sl)	2017-11-30	Mutacije K-ras in terapija s protitelesi anti-EGFR
SI2412828T1 (sl)	2013-10-30	Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr
GB0719803D0 (en)	2007-11-21	Therapeutic compounds and their use
GB0719644D0 (en)	2007-11-14	Therapeutic compounds and their use
EP2038041A4 (en)	2010-02-17	THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER
GB0803018D0 (en)	2008-03-26	Therapeutic compounds and their use
ZA200806723B (en)	2009-09-30	Combination therapy using anti-EGFR and anti-Her2 antibodies
GB0804685D0 (en)	2008-04-16	Therapeutic compounds and their use
GB0724251D0 (en)	2008-02-06	Therapeutic compounds and their use
GB0722680D0 (en)	2007-12-27	Therapeutic compounds and their use
GB0807609D0 (en)	2008-06-04	Therapeutic compounds and their use
GB0817208D0 (en)	2008-10-29	Therapeutic apsap compounds and their use
GB2460181B (en)	2010-08-18	Depsipeptides and their therapeutic use
GB2460178B (en)	2010-08-18	Depsipeptides and their therapeutic use
EP2142648A4 (en)	2011-09-14	SCREENING AND ANTI-NSCLC THERAPEUTIC METHOD TARGETING THE CDCA8-AURKB COMPLEX
IL206420A0 (en)	2010-12-30	Azetidine derivatives, their preparation and their application in therapy
GB0812913D0 (en)	2008-08-20	Therapeutic compounds and their use
EP2097085A4 (en)	2010-02-10	THERAPEUTIC MATERIALS AND METHOD
EP2231163A4 (en)	2012-10-31	COMPOUNDS AND THEIR THERAPEUTIC USE
GB2460180B (en)	2011-08-17	Depsipeptides and their therapeutic use
GB0802128D0 (en)	2008-03-12	Therapeutic compounds and their use
HK1139182A (en)	2010-09-10	K-ras and b-raf mutations and anti-egfr antibody therapy
GB0705517D0 (en)	2007-05-02	Therapeutic compounds and their use
GB0821539D0 (en)	2008-12-31	Therapeutic compounds and their use
GB0815134D0 (en)	2008-09-24	Therapeutic compounds and their use